GlassScriptPhysician profile
Diana Lau
NPI 1770506537
$6,452.83
in general payments reported to CMS, 2019-2025
19 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $454 · 2021: $354 · 2022: $560 · 2023: $887 · 2024: $1,282 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,503.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,289.73 | 2019-2025 | Tavneos, Krystexxa, Otezla |
| Abbvie INC. | $1,164.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $589.14 | 2019-2024 | Benlysta |
| Janssen Biotech, INC. | $548.65 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Aurinia Pharma U.S., INC. | $525.98 | 2021-2025 | Lupkynis |
| Ucb, INC. | $404.46 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $363.77 | 2019-2021 | |
| Genentech USA, INC. | $178.59 | 2019 | |
| Pfizer INC. | $174.68 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $168.99 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $155.07 | 2022-2024 | Strensiq |
| Ipsen Biopharmaceuticals, INC | $146.21 | 2025 | Iqirvo |
| Celgene Corporation | $137.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.66 | 2019 | |
| Lilly USA, LLC | $123.28 | 2024 | Omvoh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.02 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.94 | 2025 | Entyvio |
| Astrazeneca Pharmaceuticals LP | $84.18 | 2021 | |
| Genzyme Corporation | $55.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.